Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 20

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 20
---
624,670 ordinary shares in the November 2024 Registered Direct Offering, at a combinedpurchase price of $0.5463 per pre-funded warrant and                          
 associated warrant, and after offering expenses payable by us in connection with the November 2024 Registered Direct Offering, resulting in net proceeds of approximately $8.9 million, (B) the sale of an aggregate of 5,676,396 ADSs         
 representing 85,145,940 ordinary shares at an average price of $0.29 per ADS, for aggregate gross proceeds of approximately $1.6 million, after deducting sales agent fees and estimated aggregate offering expenses payable by us and (C) the 
 issuance of 9,051,631 ADSs representing 135,774,465 ordinary shares following the cashless exercise of pre-funded warrants initially issued in the November 2024 Registered Direct Offering; and                                               |

| • | on a pro forma as adjusted basis after giving effect to the sale in this offering of (i) 34,332,122 ADSs, representing 514,981,830 ordinary shares, and warrants to purchase up to an aggregate of 50,000,000 ADSs, representing 750,000,000       
 ordinary shares, at a combined purchase price of $0.20 per ADS and associated warrant, and (ii) pre-funded warrants to purchase up to an aggregate of 15,667,878 ADSs, representing 235,018,170 ordinary shares, and warrants to purchase up to an 
 aggregate of 50,000,000 ADSs, representing 750,000,000 ordinary shares in this offering, at a combined purchase price of $0.1999 per pre-funded warrant and associated warrant, and after estimated offering expenses payable by us in connection  
 with this offering, resulting in net proceeds of approximately $8.9 million.                                                                                                                                                                       |

This table should be read in conjunction with our financial statements and the notes thereto incorporated by reference herein and the accompanying prospectus.

|                                                                                                                              |     | As of September 30, 2024 |          |   |     |           |          |   |     |                       |          |   |
|:-----------------------------------------------------------------------------------------------------------------------------|:----|:-------------------------|---------:|:--|:----|:----------|---------:|:--|:----|:----------------------|---------:|:--|
|                                                                                                                              |     | Actual                   |          |   |     | Pro Forma |          |   |     |